In Orbit Shifting Innovation, Rajiv Narang and Devika Devaiah show readers how innovators can shake the world of corporate businesses to solving critical problems.
Summary of the Book
Businesses often hit a wall when it comes to innovation, and in this process they find that innovators with the will to create solutions. These solutions are often breakthroughs which prove that innovation which reflects the passion found in its creators is often the brightest and most potent in shifting the orbit that businesses fall into. This book uses examples and anecdotes from prominent businesses, entrepreneurs, public services and the social sector to illuminate how businesses can turn their fortunes around by relying not on history but on transformative solutions. The authors show the obstacles to innovation and explain how to overcome them and maximize the effects of transformative change.
About the Authors
Rajiv Narang is the Founder and Managing Director of Erehwon, a 20-year-old pioneering innovation firm. He is recognized as India’s Innovation Thought Leader, and was an integral part of the National Planning Commission panel to recommend ‘India’s Innovation Strategy’, and the lead architect of the ‘Innovation for India’ Foundation. With his unparalleled insight into business, social and public service innovation, Rajiv has inspired leaders to adopt innovation and led a rich portfolio of strategic initiatives with organizations like Unilever, Novartis, Bank of America and the Government of Karnataka, and Azim Premji Foundation etc.
Devika Devaiah is a Director of Erehwon and a globally established speaker. She has a cutting-edge insight into innovation having led a variety of breakthrough research initiatives over the last 15 years into challenger organizations, trans-world partnerships, and orbit-shifting innovation. Devika has a unique ability to integrate business, organization and leadership paradigms resulting in fresh perspectives and breakthrough opportunities in organizations like Unilever, Walt Disney, Intel, Savola, and AstraZeneca.